Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4612545 | 0.88 | HMGCR (0.32) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL4611947 | 0.83 | CA1 (0.33) | — | |
| SCHEMBL12251197 | 0.76 | ALDH1A1 (0.39) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL12446236 | 0.76 | — | — | |
| SCHEMBL27897518 | 0.69 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL16440226 | 0.69 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| SCHEMBL2612030 | 0.67 | ALDH1A1 (0.41) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL2914550 | 0.67 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL104505 | 0.67 | — | — | |
| SCHEMBL5592257 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1238962-B1 | A process for the preparation of michael-adducts | FIRMENICH & CIE (CH) | 2008-02-27 | — | — | EP | claimed |
| US-6686498-B2 | REACTING AN ALPHA, BETA-DISUBSTITUTED, OR AN ALPHA, BETA, BETA-TRISUBSTITUTED, ALPHA, BETA-UNSATURATED KETONE WITH A BETA-KETOESTER OR A BETA-DIKETONE; COUPLING; BYPRODUCT INHIBITION | FIRMENICH SA (CH) | 2004-02-03 | — | — | US | claimed |
| US-20020128504-A1 | Process for the preparation of Michael-adducts | FIRMENICH SA (CH) | 2002-09-12 | — | — | US | claimed |
| EP-1238962-A1 | A process for the preparation of michael-adducts | FIRMENICH SA (CH) | 2002-09-11 | — | — | EP | claimed |
| EP-1238962-B1 | A process for the preparation of michael-adducts | FIRMENICH & CIE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-6686498-B2 | REACTING AN ALPHA, BETA-DISUBSTITUTED, OR AN ALPHA, BETA, BETA-TRISUBSTITUTED, ALPHA, BETA-UNSATURATED KETONE WITH A BETA-KETOESTER OR A BETA-DIKETONE; COUPLING; BYPRODUCT INHIBITION | FIRMENICH SA (CH) | 2004-02-03 | — | — | US | disclosed |
| US-20020128504-A1 | Process for the preparation of Michael-adducts | FIRMENICH SA (CH) | 2002-09-12 | — | — | US | disclosed |
| EP-1238962-A1 | A process for the preparation of michael-adducts | FIRMENICH SA (CH) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128504-A1 | Process for the preparation of Michael-adducts | AKR1A1, AKR1B1, AKR1B10 | ALDH1A1 24/4885TDP1 2003/4885HMGCR 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.